Published in final edited form as:

Bioorg Med Chem Lett. 2012 May 15; 22(10): 3567–3570. doi:10.1016/j.bmcl.2012.03.013.

Synthesis and Biological Activity of 2-Aminothiazoles as Novel Inhibitors of PGE₂ Production in Cells

Breland Smith^{a,b}, Hui-Hua Chang^c, Federico Medda^a, Vijay Gokhale^d, Justin Dietrich^a, Angela Davis^d, Emmanuelle J. Meuliet^c, and Christopher Hulme^{a,d}

^aBIO5 Oro Valley, The University of Arizona, 1580 E. Hanley Blvd., Oro Valley, AZ 85737.

^b Department of Chemistry & Biochemistry, The University of Arizona, 1306 E. University Blvd., Tucson, AZ 85721.

^c Departments of Nutritional Sciences and Molecular and Cellular Biology, Arizona Cancer Center, The University of Arizona, 1515 N. Campbell Ave., Tucson, AZ 85724.

^dDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, AZ 85721.

Abstract

This report presents the synthesis and biological evaluation of a collection of 2-aminothiazoles as a novel class of compounds with the capability to reduce the production of PGE₂ in HCA-7 human adenocarcinoma cells. A total of 36 analogs were synthesized and assayed for PGE₂ reduction, and those with potent cellular activity were counter screened for inhibitory activity against COX-2 in a cell free assay. In general, analogs bearing a 4-phenoxyphenyl substituent in the R² position were highly active in cells while maintaining negligible COX-2 inhibition. Specifically, compound **5I** (R¹=Me, R²=4-OPh-Ph, R³=CH(OH)Me) exhibited the most potent cellular PGE₂ reducing activity of the entire series (EC₅₀ = 90 nM) with an IC₅₀ value for COX-2 inhibition of > 5 μM *in vitro*. Furthermore, the anti-tumor activity of analog **1a** was analyzed in xenograft mouse models exhibiting promising anti-cancer activity.

Inflammatory processes are implicated in 25% of all cancers and chronic inflammation has been shown to promote the growth of malignant tissues. Indeed, prostaglandin E₂ (PGE₂) has been identified as a key mediator of pain and inflammation and is overexpressed in various cancers. Definitive evidence suggests that PGE₂ is the dominant prostaglandin involved in the growth of tumors associated with colon, lung, breast, head, and neck cancers.¹⁻⁴ Interestingly recent studies support a role for PGE₂ in most if not all of the six hallmarks of cancer named by Hanahan and Weinberg; the mechanisms by which PGE₂ induces these cellular capabilities can vary amongst cancer types.⁴⁻⁶

Traditionally, prostaglandin synthesis has been modulated primarily through the use of non-steroidal anti-inflammatory drugs (NSAIDs), including non-specific cyclooxygenase (COX) -1 and 2 inhibitors (Aspirin, Tylenol, and Ibuprofen) and specific COX-2 inhibitors (Bextra®, Celebrex®, and Vioxx®). Incidentally, patients taking NSAIDs for chronic inflammatory disorders such as rheumatoid arthritis are associated with a decreased

© 2012 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

incidence of colon cancer, and high doses of NSAIDs have been shown to cause colorectal tumor regression.¹⁻⁴ Furthermore, exogenous treatment with PGE₂ blocks NSAID-induced tumor regression.¹ Therefore, it is believed that the anti-cancer effects of COX inhibitors are ultimately due to a reduction of PGE₂ levels, although there is a downside of NSAID treatment in that the high doses and chronic usage required for anti-cancer activity lead to adverse target-based side effects including gastrointestinal intolerance, heart attacks, and blood clotting.¹⁻⁴ Thus, these safety implications have motivated research efforts focused on the reduction of PGE₂ levels through alternate mechanisms.⁷⁻¹¹

Herein we report the biological evaluation of a series of 2-aminothiazole analogs as a novel class of small molecules with PGE₂ reducing character in HCA-7 colon cancer cells. The general structure for analogs **1-5** is shown in **Figure 1**.

2-Aminothiazole analogs depicted in **Table 1 (1a-h, 2a-g, 3a-d, 4a-e)** as well as structures **5c-i** from **Table 2** were assembled by employing a microwave assisted Hantzsch reaction (**Scheme 1**).^{12, 16} Compounds **5j** and **5k-l** were obtained by reduction of the ketone functionality of **5i** and **5f**, respectively (**Scheme 1**). Alternately, compounds **5a** and **5b** were synthesized in two-steps proceeding through an amidino-thiourea intermediate (**6**) (**Scheme 2**).¹³ Purities of all analogs were assessed by HPLC/MS analysis. All compounds showed purity level greater than 95%, as judged by UV absorbance at 254 nm and 214 nm as well as evaporative light scattering (ELS).

Initially, all compounds (**Figure 2-3**) were screened for their ability to reduce PGE₂ production in HCA-7 colon cancer cells at 1 μ M concentration; activities are summarized in **Tables 1-2** as percentage reduction of PGE₂ levels.¹⁷ As a means for tuning out COX-2 activity, compounds that exhibited reduction of PGE₂ levels higher than 70% were tested for COX-2 inhibition at 5 μ M in an *in vitro* cell free assay,¹⁸ with Celecoxib incorporated as a positive control in both PGE₂ and COX-2 assays.¹⁴ IC₅₀ values for COX-2 inhibition were determined only for compounds that exhibited inhibitory activity against COX-2 greater than 50%. Only compounds that exhibited more than 70% reduction of PGE₂ levels, but did not show more than 50% COX-2 inhibition were tested further for EC₅₀ determination.

Aminothiazole analogs **1a-h** consist of a *para*-chlorophenyl group at the C-4 position (R¹) of the thiazole ring and varying substituents at other positions. Presence of 4-phenoxyphenyl (**1a**), 3,4-methylenedioxyphenyl (**1b**), or 3-methoxyphenyl (**1c**) at the R² position leads to good activity (reduction in PGE₂ levels = 76-94%). Compounds **1d-e** were characterized by lower activity (reduction in PGE₂ levels = 51%) when compared to compounds **1a-c**. Substitution with a polar cyano group (**1f**) also resulted in significant loss of activity (reduction in PGE₂ levels = 23%) possibly due to a decreased ability to permeate the cellular membrane. Surprisingly, analog **1g** bearing a methyl group on the amino functionality (R⁴), resulted in good cellular activity despite the polar 4-hydroxyphenyl substituent at R² (reduction in PGE₂ levels = 86%). Similarly, substitution of a methyl group at the C-5 position (R³) of the aminothiazole ring, as in compound **1h**, is also well tolerated (reduction in PGE₂ levels 89%). Compounds from this group exhibited relatively strong inhibition of COX-2 *in vitro* (IC₅₀ = 0.84-1.39 μ M), with exceptions represented by **1a** and **1h** (IC₅₀ > 5 μ M). These two compounds were then tested for EC₅₀ determination and show similar EC₅₀ values for cellular PGE₂ reduction (0.28 μ M and 0.29 μ M, respectively).

Compounds **1a** and **2a-g** consist of a *para*-phenoxyphenyl group on the amino functionality (R²). These compounds show a moderate to high reduction of PGE₂ levels (42-89%). In this series, compounds characterized by a *para*-fluorophenyl (**2b**) or a methoxyphenyl (**2c-e**) substituent at C-4 of the 2-aminothiazole core (R¹) exhibited the highest level of PGE₂ reduction (80-89%). Movement of the methoxy group amongst *ortho*, *meta*, and *para*

positions on the phenyl ring at R¹ did not significantly influence the observed biological activity (**2c-e**). However, the activity of compound **2a** (reduction of PGE₂ levels 80%) suggested that the presence of a substituent on the phenyl ring of R¹ was not essential. Presence of bulky lipophilic substituents (naphthyl, **2f**; 4-cyclohexylphenyl, **2g**) at the R¹ position results in lower activity (reduction in PGE₂ levels = 54% and 42%, respectively) when compared to compound **2a**. None of these compounds **2a-g** showed significant COX-2 inhibitory activity (IC₅₀ values > 5 μM). Notably, analogs **2b** and **2c** exhibited the lowest EC₅₀ values for PGE₂ reduction of this group (0.12 and 0.18 μM, respectively). Other analogs showed EC₅₀ values similar to analog **1a** (0.24-0.33 μM). In general, analogs bearing a *para*-phenoxyphenyl substituent at R² (**1a** and **2a-e**) showed negligible inhibitory activity on COX-2 while still strongly reducing PGE₂ levels in cells.

Replacement of the previous *para*-phenoxyphenyl group at R² (**2a-g**) with a *para*-methoxyphenyl group (**3a-c**) resulted in an analogous activity trend. Compounds **2e** and **3c** bearing a *para*-methoxyphenyl at R¹ both show similar reduction of PGE₂ levels (80% and 74%, respectively). Additionally, compounds **3a** and **3b** bearing 4-methylphenyl and 3,4-dimethylphenyl substituents, respectively, showed cellular activities comparable to analogs **2a**, **2f**, and **2g** also containing hydrophobic moieties at C-4 (reduction in PGE₂ levels = 37-74%, **3a-b** and 42-80%, **2a, f-g**). Interestingly, when the 4-methoxyphenyl group on R² of analog **3c** was exchanged with a 4-methylphenyl to give analog **3d**, an increase in cellular PGE₂ reducing activity was observed (reduction in PGE₂ levels = 74% and 92%, respectively). Although transitioning from a *para*-phenoxyphenyl (**2a-g**) to a *para*-methoxyphenyl (**3a-c**) at R² does not significantly affect PGE₂ reducing activity, the COX-2 inhibition of **3b-c** (IC₅₀ = 1.20 and 1.37 μM, respectively) is considerably stronger than for **2a-e** (IC₅₀ values > 5 μM).

Introduction of a 3,4-methylenedioxyphenyl substituent on the amine nitrogen (R²) resulted in a dramatic reduction of cellular PGE₂ levels (**4a-e**, 98-86%). Compound **4a**, characterized by an un-substituted phenyl ring at the C-4 position of the 2-aminothiazole (R¹) showed the highest activity (reduction in PGE₂ levels = 98%). Unfortunately, the high levels of cellular PGE₂ reducing activity observed with this group of compounds is always associated with relatively strong inhibition of COX-2 activity (**4a-e**; IC₅₀ = 0.41- 0.93 μM). Thus, the strong cellular activity of **4a-e** as well as analogs **3b-c** may arise, at least in part, from inhibitory effects on COX-2. However the overall cellular PGE₂ reducing activity of these analogs cannot be fully explained by COX-2 inhibition and rather is likely the result of inhibitory activity on more than one target. Furthermore, although tuning out COX-2 inhibition has proven to be clinically important in terms of safety, PGE₂ reducing therapeutics functioning primarily through a mechanism not involving COX, but maintaining weak COX-2 inhibition, may still be therapeutically useful if PGE₂ biosynthesis can be blocked while COX activity remains at least at a basal level.¹⁻⁴

Compounds **5a-i** containing a keto moiety (acetyl or benzyl group) at the R³ position (**Table 2**) were moderately active to inactive (0-59%; except **5f**, reduction of PGE₂ levels = 88%). Overall, analogs characterized by the presence of a methyl at C-4 (R¹) and an acetyl group at C-5 (R³) of the aminothiazole (**5e-i**) exhibited higher PGE₂ reducing character than analogs **5a-d**. Of interest, when the acetyl group of **5i** was reduced to the corresponding ethyl chain (R³, **5j**) a marked reduction of PGE₂ levels was observed (94%). In contrast, reduction of the ketone functionality of **5f** to the corresponding ethyl group (**5k**) did not lead to a significant change in activity (reduction in PGE₂ levels = 88% and 87%, respectively). Interestingly, compound **5l** with -CH(OH)Me at R³ was the most potent compound identified in this report (EC₅₀ = 0.09 μM). Compound **5l** was slightly more active than its parent analog **5f** (EC₅₀ = 0.39 μM) and its fully reduced derivative **5k** (EC₅₀ = 0.37 μM).

Active compounds **5f** and **5j-l** were analyzed for COX-2 activity, showing little to no inhibition at 5 μ M.

In conclusion, we have synthesized and tested a series of 2-aminothiazole congeners with the ability to reduce the production of PGE₂ in HCA-7 cells. A total of 36 aminothiazoles were evaluated, and active compounds with limited COX-2 inhibition were identified. Compound **1a** was also evaluated for its effect on tumor growth in mouse xenograft models under three different cell lines, and was confirmed to have promising anti-cancer activity. Tumor vs. control values (T/C) were 61% and 40% for HCA-7 human colonic adenocarcinoma and SW837 rectum adenocarcinoma cell lines, respectively, under a dosing schedule of 200 mg/kg over 5 days ($P < 0.05$). Additionally, a T/C value of 38% was observed in A549 human lung adenocarcinoma cells after treatment with 100 mg/kg over a period of 10 days ($P < 0.05$).¹⁵ Work is on-going to identify alternate modes of action that may feasibly lead to reduced PGE₂ levels. Future synthetic efforts will be focused on further development of aminothiazoles with diverse substitution patterns that will continue to reveal important structure activity relationship features and aid in the identification of more potent compounds with anticancer activity *in vivo*.

Acknowledgments

The authors would like to thank financial support provided by an NIH training grant research fellowship (BCP Fellowship, Grant # 5T32GM008804-09), the University of Arizona College of Pharmacy for start-up funds and SR01CA138702. Finally, the authors graciously acknowledge Kristen Keck for selected compound purification, Alex Laetsch for compound management and Nicole Schechter for group coordination.

References

1. Iyer JP, Srivastava PK, Dev R, Dastidar SG, Ray A. Expert Opin. Ther. Tar. 2009; 13:849.
2. Friesen RW, Mancini JA. J. Med. Chem. 2008; 51:4059. [PubMed: 18459759]
3. Tawab MA, Zettl H, Zsilavec MS. Curr. Med. Chem. 2009; 16:2042. [PubMed: 19519380]
4. Wang D, DuBois R. Nat. Rev. Cancer. 2010; 10:181. [PubMed: 20168319]
5. a Hanahan D, Weinberg RA. Cell. 2000; 100:57. [PubMed: 10647931] b Hanahan D, Weinberg RA. Cell. 2011; 144:646. [PubMed: 21376230]
6. Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. Carcinogenesis. 2009; 30:377. [PubMed: 19136477]
7. Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Methot N, Rubin J, Friesen W. Bioorg. Med. Chem. Lett. 2005; 15:3352. [PubMed: 15953724]
8. Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Masse F, Methot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW. Bioorg. Med. Chem. Lett. 2007; 17:6816. [PubMed: 18029174]
9. Giroux A, Boulet L, Brideau C, Chau A, Claveau D, Cote B, Ethier D, Frenette R, Gagnon M, Guay J, Guiral S, Mancini JA, Martins E, Masse F, Methot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW. Bioorg. Med. Chem. Lett. 2009; 19:5837. [PubMed: 19748780]
10. Moon JT, Jeon JY, Park HA, Noh Y-S, Lee K-T, Kim J, Choo DJ, Lee JY. Bioorg. Med. Chem. 2010; 20:734.
11. Hamza A, Zhao X, Tong M, Tai HH, Zhan CG. Bioorg. Med. Chem. 2011; 19:6077. [PubMed: 21920764]
12. Kabalka GW, Mereddy AR. Tetrahedron Lett. 2006; 47:5171.
13. Masquelin T, Obrecht DA. Tetrahedron. 2001; 57:153.
14. Isakson PC, Zhang YY, Veenhuizen AW, Seibert K, Perkins WE, Koboldt CM, Gregory SA, Cogburn JN, Burton EG, Anderson GD, Yu SS, Rogier DJ, Rogers RS, Miyashiro JM, Malecha JW, Lee JF, Graneto MJ, Docter S, Collins PW, Carter JS, Bertenshaw SR, Talley JJ, Penning TDJ. Med. Chem. 1997; 40:1347.

15. Chang HH, Song Z, Wisner L, Tripp T, Gokhale V, Meuillet EJ. Invest. New Drugs. doi: 10.1007/s10637-011-9748-8.
16. *General procedure for the preparation of 2e*: 2-bromo-1-(4-methoxyphenyl)ethanone **7** (0.437 mmol, 100 mg) and N-(4-phenoxyphenyl)thiourea **8** (0.437 mmol, 107 mg) were suspended in ethanol (2 mL) and subjected to microwave irradiation at 110 °C for 10 min. The resulting solution was diluted with CH₂Cl₂ (10 mL) and washed with a saturated aqueous solution of Na₂CO₃ (20 mL). The organic layer was dried (MgSO₄) and evaporated under reduced pressure. The resulting crude residue was purified by silica gel column chromatography (EtOAc-hexanes, gradient) using a ISCO™ system to give aminothiazole **2e** as a light orange solid (0.246 mmol, 92 mg, 56%). mp: 125.5-127 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ 10.25 (br s, 1H), 7.85 (d, *J* = 8.7 Hz, 2H), 7.77 (d, *J* = 8.9 Hz, 2H), 7.37 (t, *J* = 7.8 Hz, 2H), 7.14 (s, 1H), 7.13 – 7.02 (m, 3H), 7.02 – 6.94 (m, 4H), 3.79 (s, 3H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 163.9, 159.7, 158.6, 150.9, 150.8, 138.4, 130.8, 128.3, 127.9, 123.5, 120.9, 119.2, 118.4, 114.8, 101.4, 56.0. LC-MS [MH]⁺ 375.1.
17. **PGE₂ production assay**: Cells were seeded in 6-well plates and incubated overnight in DMEM/10% FBS. They were serum starved for the next 18 h. Cells were then treated with 10 ng/ml IL-1β and increasing concentration of compounds (dissolved in DMSO) in 1 mL serum-free medium. After 72 h of incubation, the supernatants were collected for PGE₂ level detection using the PGE₂ EIA kit (R&D Systems).
18. **COX-2 cell-free assay**: COX-2 activity was measured by a COX Fluorescent inhibitor screen assay kit following the manufacturer's instructions (Cayman Chemical, <http://www.caymanchem.com>).

Figure 1.
General structure of aminothiazoles **1-5**

Scheme 1. Synthesis of aminothiazoles **1a-h, 2a-g, 3a-d, 4a-e, 5c-l**

Scheme 2.
Synthesis of aminothiazoles **5a-b**

Figure 2.
Structure of 2-aminothiazoles analogs **1-4**.

5a-l

Figure 3.
Structure of 2-aminothiazoles analogs **5**.

Table 1

Biological activity of 2-aminothiazoles analogs 1-4. ^{abcdef}

Cmpd	R ¹	R ²	R ³	R ⁴	PGE ₂ (%) ^c	COX-2 (%) ^d	COX-2 IC ₅₀ μM ^e	PGE ₂ EC ₅₀ μM ^f
1a	4-Cl-Ph	4-OPh-Ph	H	H	75.5 ± 7	32.1 ± 5	> 10	0.28 ± 0.11
1b	4-Cl-Ph	3-OCH ₂ O-4-Ph	H	H	94.2 ± 3	68.8 ± 8	0.84 ± 0.20	-
1c	4-Cl-Ph	3-OMe-Ph	H	H	78.3 ± 3	55.1 ± 3	1.39 ± 0.34	-
1d	4-Cl-Ph	Ph	H	H	51.0 ± 8	-	-	-
1e	4-Cl-Ph	1-naphthyl	H	H	51.4 ± 8	-	-	-
1f	4-Cl-Ph	4-CN-Ph	H	H	23.1 ± 10	-	-	-
1g	4-Cl-Ph	4-OH-Ph	H	Me	85.8 ± 8	84.2 ± 13	1.08 ± 0.37	-
1h	4-Cl-Ph	4-OMe-Ph	Me	H	89.3 ± 2	12.0 ± 1	> 5	0.29 ± 0.10
2a	Ph	4-OPh-Ph	H	H	79.6 ± 10	31.0 ± 1	> 5	0.33 ± 0.15
2b	4-F-Ph	4-OPh-Ph	H	H	87.9 ± 1	43.4 ± 8	> 5	0.12 ± 0.04
2c	2-OMe-Ph	4-OPh-Ph	H	H	82.0 ± 3	38.9 ± 5	> 5	0.18 ± 0.02
2d	3-OMe-Ph	4-OPh-Ph	H	H	88.9 ± 1	40.3 ± 4	> 5	0.29 ± 0.13
2e	4-OMe-Ph	4-OPh-Ph	H	H	80.4 ± 2	40.8 ± 5	> 5	0.24 ± 0.05
2f	2-naphthyl	4-OPh-Ph	H	H	53.5 ± 1	-	-	-
2g	4-Cy-Ph	4-OPh-Ph	H	H	41.6 ± 16	-	-	-
3a	4-Me-Ph	4-OMe-Ph	H	H	37.3 ± 6	-	-	-
3b	3,4-diMe-Ph	4-OMe-Ph	H	H	73.9 ± 2	69.3 ± 5	1.20 ± 0.19	-
3c	4-OMe-Ph	4-OMe-Ph	H	H	73.6 ± 3	66.8 ± 3	1.37 ± 0.08	-
3d	4-OMe-Ph	4-Me-Ph	H	H	91.5 ± 1	73.1 ± 6	0.81 ± 0.16	-
4a	Ph	3-OCH ₂ O-4-Ph	H	H	98.2 ± 1	114.2 ± 1	0.41 ± 0.11	-
4b	2-Cl-Ph	3-OCH ₂ O-4-Ph	H	H	85.9 ± 3	84.8 ± 3	0.91 ± 0.10	-
4c	2-OMe-Ph	3-OCH ₂ O-4-Ph	H	H	89.0 ± 4	91.3 ± 4	0.93 ± 0.02	-
4d	3-OMe-Ph	3-OCH ₂ O-4-Ph	H	H	94.4 ± 2	86.0 ± 8	0.92 ± 0.38	-
4e	4-OMe-Ph	3-OCH ₂ O-4-Ph	H	H	96.2 ± 1	94.4 ± 2	0.91 ± 0.06	-

^a Celecoxib was used as a positive control (PGE₂, 5.70 ± 3.28% and EC₅₀ = 1.15 ± 0.06 nM; COX-2, 85.6 ± 4.4% inhibition and IC₅₀ = 0.03 ± 0.01) ¹².

^b - not determined.

^c % of inhibition of PGE₂ levels in HCA-7 cells at 1 μM concentration ± SD (*n* = 3).

^d % of inhibition of COX-2 levels *in vitro* at 5 μM concentration ± SD (*n* = 3).

^e *in vitro* IC₅₀ for COX-2 inhibition ± SD (*n* = 3).

^f EC₅₀ for PGE₂ level reduction in HCA-7 cells ± SD (*n* = 3).

Table 2

Biological activity of 2-aminothiazoles analogs 5a-l. ^{abcde fgh}

Cmpd	R ¹	R ²	R ³	PGE ₂ (%) ^d	COX-2 (%) ^e	COX-2 IC ₅₀ /μM ^f	PGE ₂ EC ₅₀ /μM ^g
5a	Ph	3-OCH ₂ O-4-Ph	C(O)Ph	NR	-	-	-
5b	Ph	4-CN-Ph	C(O)Ph	NR	-	-	-
5c	Ph	4-OMe-Ph	C(O)Ph	NR	-	-	-
5d	Ph	4-OPh-Ph	C(O)Ph	42.0 ± 6	-	-	-
5e	Me	Ph	C(O)Me	29.9 ± 1	-	-	-
5f	Me	4-OPh-Ph	C(O)Me	87.9 ± 1	28.9 ± 15	> 5	0.39 ± 0.07
5g	Me	3-OCH ₂ O-4-Ph	C(O)Me	25.3 ± 3	-	-	-
5h	Me	4-CN-Ph	C(O)Me	22.4 ± 4	-	-	-
5i	Me	4-OMe-Ph	C(O)Me	58.5 ± 4	-	-	-
5j	Me	4-OMe-Ph	Et	94.4 ± 1	49.3 ± 4	> 5	0.32 ± 0.14
5k	Me	4-OPh-Ph	Et	87.1 ± 3	41.3 ± 5	> 5	0.37 ± 0.07
5l	Me	4-OPh-Ph	CH(OH)Me	80.4 ± 3	-16.9 ± 10 ^h	> 5	0.09 ± 0.04

^a Celecoxib was used as a positive control (PGE₂, 5.70 ± 3.28% and EC₅₀ = 1.15 ± 0.06 nM; COX-2, 85.6 ± 4.4% inhibition and IC₅₀ = 0.03 ± 0.01)¹².

^b NR, no observed reduction.

^c - not determined.

^d % of inhibition of PGE₂ levels in HCA-7 cells at 1 μM concentration ± SD (*n* = 3).

^e % of inhibition of COX-2 levels *in vitro* at 5 μM concentration ± SD (*n* = 3).

^f *in vitro* IC₅₀ for COX-2 inhibition ± SD (*n* = 3).

^g EC₅₀ for PGE₂ level reduction in HCA-7 cells ± SD (*n* = 3).

^h to be considered as no inhibition of activity rather than induction of activity.